$AMST
Amesite Inc. Stock $amst

$amst Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000121390024083458 Filed on September 30, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$11.25K	$27.84K	$166.9K
YoY Change	-82.24%	-76.8%	-80.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$798.9K	$1.238M	$3.672M
YoY Change	17.51%	11.5%	3.56%
% of Gross Profit
Research & Development	$139.7K
YoY Change	-58.12%
% of Gross Profit
Depreciation & Amortization	$118.3K	$119.5K	$533.7K
YoY Change	-22.37%	-20.34%	-21.81%
% of Gross Profit
Operating Expenses	$938.6K	$1.238M	$4.747M
YoY Change	-7.37%	11.5%	-6.37%
Operating Profit	-$927.3K		-$4.580M
YoY Change	-2.38%		8.41%
Interest Expense	$19.30K	$28.83K	$176.5K
YoY Change	-67.45%	-27.93%	152.1%
% of Operating Profit
Other Income/Expense, Net	$19.30K	$0.00	$176.5K
YoY Change			147.83%
Pretax Income	-$908.1K	-$1.181M	-$4.403M
YoY Change	1.95%	24.31%	6.1%
Income Tax
% Of Pretax Income
Net Earnings	-$908.0K	-$1.181M	-$4.403M
YoY Change	1.95%	24.31%	6.02%
Net Earnings / Revenue	-8071.51%	-4241.99%	-2638.52%
Basic Earnings Per Share	-$0.34		-$1.73
Diluted Earnings Per Share	-$0.34	-$0.46	-$1.73
COMMON SHARES
Basic Shares Outstanding	2.792M shares	2.542M shares	2.542M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.435M	$2.071M	$2.071M
YoY Change	-69.06%	-61.36%	-61.36%
Cash & Equivalents	$1.435M	$2.071M	$2.071M
Short-Term Investments
Other Short-Term Assets	$1.062M	$503.5K	$503.5K
YoY Change	1288.81%	357.72%	357.72%
Inventory
Prepaid Expenses
Receivables		$30.06K	$30.06K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.497M	$2.605M	$2.605M
YoY Change	-47.24%	-52.49%	-52.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$58.45K	$64.78K	$64.78K
YoY Change	-29.27%	-27.18%	-28.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$739.3K	$709.6K	$709.6K
YoY Change	-5.24%	-18.19%	-18.44%
TOTAL ASSETS
Total Short-Term Assets	$2.497M	$2.605M	$2.605M
Total Long-Term Assets	$739.3K	$709.6K	$709.6K
Total Assets	$3.236M	$3.314M	$3.314M
YoY Change	-41.29%	-47.81%	-47.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$56.01K	$48.91K	$48.91K
YoY Change	-29.0%	-30.2%	-30.13%
Accrued Expenses	$762.6K	$749.6K	$749.6K
YoY Change	376.45%	435.4%	435.4%
Deferred Revenue	$24.38K
YoY Change	0.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$843.0K	$798.5K	$798.5K
YoY Change	220.14%	200.94%	195.73%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$843.0K	$798.5K	$798.5K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$843.0K	$798.5K	$798.5K
YoY Change	220.13%	195.73%	195.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$38.74M	-$37.83M
YoY Change	12.88%	13.17%
Common Stock	$280.00	$255.00
YoY Change	9.8%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.393M	$2.516M	$2.516M
YoY Change
Total Liabilities & Shareholders Equity	$3.236M	$3.314M	$3.314M
YoY Change	-41.29%	-47.81%	-47.81%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$908.0K	-$1.181M	-$4.403M
YoY Change	1.95%	24.31%	6.02%
Depreciation, Depletion And Amortization	$118.3K	$119.5K	$533.7K
YoY Change	-22.37%	-20.34%	-21.81%
Cash From Operating Activities	-$488.3K	-$654.4K	-$2.814M
YoY Change	-25.88%	-2.33%	-13.4%
INVESTING ACTIVITIES
Capital Expenditures	$148.0K	$147.1K	$1.166K
YoY Change		33.73%	-95.7%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$148.0K	-$147.1K	-$375.9K
YoY Change	126.99%	33.73%	-5.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-$488.3K	-654.4K	-$2.814M
Cash From Investing Activities	-$148.0K	-147.1K	-$375.9K
Cash From Financing Activities		0.000
Net Change In Cash	-$636.3K	-801.5K	-$3.190M
YoY Change	-12.12%	2.76%	77.73%
FREE CASH FLOW
Cash From Operating Activities	-$488.3K	-$654.4K	-$2.814M
Capital Expenditures	$148.0K	$147.1K	$1.166K
Free Cash Flow	-$636.3K	-$801.5K	-$2.815M
YoY Change	-3.42%	2.76%	-14.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.73
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.68
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-39553
CY2024	dei	Entity Registrant Name EntityRegistrantName	AMESITE INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3431718
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	607 Shelby Street
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 700 PMB 214
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Detroit
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48226
CY2024	dei	City Area Code CityAreaCode	(734)
CY2024	dei	Local Phone Number LocalPhoneNumber	876-8141
CY2024	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
CY2024	dei	Trading Symbol TradingSymbol	AMST
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	4268497.5	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2792440	shares
CY2024	dei	Auditor Firm AuditorFirmId	76
CY2024	dei	Auditor Name AuditorName	Turner, Stone & Company, L.L.P.
CY2024	dei	Auditor Location AuditorLocation	Dallas, Texas
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2071016	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5260661	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30060	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	403489	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	106679	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	2604565	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	5482340	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	64784	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88966	usd
CY2024Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	644828	usd
CY2023Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	778446	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	709612	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	867412	usd
CY2024Q2	us-gaap	Assets Assets	3314177	usd
CY2023Q2	us-gaap	Assets Assets	6349752	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	48907	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	70070	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	655275	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	64500	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	53958	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	94283	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	76799	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	798465	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	265327	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2542440	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2542440	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2542440	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2542440	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	255	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	255	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40348958	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39514489	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37833501	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33430319	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2515712	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6084425	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3314177	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6349752	usd
CY2024	us-gaap	Revenues Revenues	166881	usd
CY2023	us-gaap	Revenues Revenues	845009	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2908289	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2492777	usd
CY2024	amst	Technology And Content Development TechnologyAndContentDevelopment	1074328	usd
CY2023	amst	Technology And Content Development TechnologyAndContentDevelopment	1523547	usd
CY2024	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	763915	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1053193	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	4746532	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	5069517	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-4579651	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4224508	usd
CY2024	us-gaap	Investment Income Interest InvestmentIncomeInterest	176469	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	72824	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1619	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	176469	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	71205	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-4403182	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4153303	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.73
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.68
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2542440	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2469890	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	8135752	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4153303	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	71940	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1850501	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	179535	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6084425	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-4403182	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	834469	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2515712	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-4403182	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4153303	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	533667	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	682483	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	834469	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	179534	usd
CY2023	amst	Value Of Common Stock Issued In Exchange For Consulting Services ValueOfCommonStockIssuedInExchangeForConsultingServices	71938	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15060	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	455	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	296810	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-453405	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-21163	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-52212	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	590775	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-109556	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-53958	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-288714	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	17483	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-32296	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2813779	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3249176	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1166	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27124	usd
CY2024	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	374700	usd
CY2023	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	368909	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-375866	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-396033	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1850503	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1850503	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3189645	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1794706	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5260661	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7055367	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2071016	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5260661	usd
CY2024	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 - Nature of Business and Liquidity</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Amesite Inc. (the “Company”) was incorporated in November 2017. </span>Amesite is a pioneering technology company specializing in the development and marketing of B2C and B2B AI-driven solutions, including its higher ed platform that offers professional learning. Leveraging its proprietary AI infrastructure, Amesite offers cutting-edge applications that cater to both individual and professional needs. NurseMagic™, the company’s mobile healthcare app, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses on patient care, medications, and handling challenging workplace situations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Going Concern</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The accompanying financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is developing its customer base and has not completed its efforts to establish a stabilized source of revenue sufficient to cover its expenses. The Company has had a history of net losses and negative cash flows from operating activities since inception and expects to continue to incur net losses and use cash in its operations in the foreseeable future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">The assessment of the Company’s ability to meet its future obligations is inherently judgmental, subjective and susceptible to change. Based on their current forecast, management believes that it may not have sufficient cash and cash equivalents to maintain the Company’s planned operations for the next twelve months following the issuance of these financial statements. The Company has considered both quantitative and qualitative factors that are known or reasonably knowable as of the date of these financial statements are issued and concluded that there are conditions present in the aggregate that raise substantial doubt about the Company’s ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In response to the conditions, management plans include generating cash by completing financing transactions, which may include offerings of common stock. However, these plans are subject to market conditions, and are not within the Company’s control, and therefore, cannot be deemed probable. There is no assurance that the Company will be successful in implementing their plans. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</p>
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	usd
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	3618991	usd
CY2022Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	3250082	usd
CY2024	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	374700	usd
CY2023	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	368909	usd
CY2024Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	3993691	usd
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	3618991	usd
CY2023Q2	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	2840545	usd
CY2022Q2	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	2183408	usd
CY2024	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	508318	usd
CY2023	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	657137	usd
CY2024Q2	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	3348863	usd
CY2023Q2	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	2840545	usd
CY2024Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	644828	usd
CY2023Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	778446	usd
CY2024	us-gaap	Deferred Policy Acquisition Cost Amortization Expense Other DeferredPolicyAcquisitionCostAmortizationExpenseOther	508318	usd
CY2023	us-gaap	Deferred Policy Acquisition Cost Amortization Expense Other DeferredPolicyAcquisitionCostAmortizationExpenseOther	657137	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	354055	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	200123	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	90650	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	644828	usd
CY2024	us-gaap	Revenues Revenues	166881	usd
CY2023	us-gaap	Revenues Revenues	845009	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.97	pure
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.87	pure
CY2024	us-gaap	Revenues Revenues	166881	usd
CY2023	us-gaap	Revenues Revenues	845009	usd
CY2024Q2	us-gaap	Deposit Contracts Assets DepositContractsAssets	15000	usd
CY2023Q2	us-gaap	Deposit Contracts Assets DepositContractsAssets	0	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	53958	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	342672	usd
CY2024	us-gaap	Gross Transaction Volume GrossTransactionVolume	112923	usd
CY2023	us-gaap	Gross Transaction Volume GrossTransactionVolume	556295	usd
CY2024	amst	Revenue Recognized From Continuing Operations RevenueRecognizedFromContinuingOperations	166881	usd
CY2023	amst	Revenue Recognized From Continuing Operations RevenueRecognizedFromContinuingOperations	845009	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	53958	usd
CY2024	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	53958	usd
CY2023	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	311806	usd
CY2024	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	633000	shares
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	758079	shares
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Risks and Uncertainties </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company operates in an industry subject to rapid change. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, and other risks associated with an early-stage company, including the potential risk of business failure.</p>
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	182343	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	181177	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	117559	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	92211	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	64784	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88966	usd
CY2023	us-gaap	Depreciation Depreciation	25349	usd
CY2024	us-gaap	Depreciation Depreciation	25349	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024	amst	Purchase Price PurchasePrice	1500000	usd
CY2024	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1360000	usd
CY2024Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	36
CY2022	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	12500	shares
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	6
CY2022Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	286459	shares
CY2022Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.6
CY2022Q1	us-gaap	Stock Issued During Period Shares Period Increase Decrease StockIssuedDuringPeriodSharesPeriodIncreaseDecrease	312500	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Period Increase Decrease StockIssuedDuringPeriodSharesPeriodIncreaseDecrease	312500	shares
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3000000	usd
CY2022Q1	amst	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	2509550	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	15625	usd
CY2022Q1	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	12
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10417	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	61250	usd
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	348485	shares
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1850000
CY2022Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	348485
CY2022Q3	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	9.84
CY2024	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	17424	usd
CY2024	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	8.25
CY2024	amst	Warrants Issued WarrantsIssued	42454	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.25
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.84
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	123257	shares
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	843035	shares
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0436	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.125	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	263599	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M2D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	26558	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	31.2
CY2022	amst	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terminated Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerminatedTerm	P7Y10M6D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	237041	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.73
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M20D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	6292	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.39
CY2024	amst	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Granted Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualGrantedTerm2	P9Y9M
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	8114	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	20.77
CY2024	amst	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terminated Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerminatedTerm	P5Y8M19D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	235219	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.05
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y5M15D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.3
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	23500	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	8114	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	26558	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	172702	usd
CY2021Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	28090	shares
CY2024	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	18137	usd
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	179534	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	65957	usd
CY2024	us-gaap	Restricted Stock Expense RestrictedStockExpense	600000	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	900000	usd
CY2024Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	508488	shares
CY2024Q2	amst	Exercise Of Incentive Stock Options ExerciseOfIncentiveStockOptions	508488	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	422	shares
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-924668	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-872194	usd
CY2024	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-220159	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-207665	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1444534	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1069422	usd
CY2024	amst	Permanent Differences PermanentDifferences	293	usd
CY2023	amst	Permanent Differences PermanentDifferences	10436	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7202000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6292000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	350655	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	818755	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	94392	usd
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	104596	usd
CY2024Q2	amst	Deferred Tax Assets Tax Depreciation DeferredTaxAssetsTaxDepreciation	13181	usd
CY2023Q2	amst	Deferred Tax Assets Tax Depreciation DeferredTaxAssetsTaxDepreciation	10150	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	10764	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	16770	usd
CY2023Q2	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	14029	usd
CY2024Q2	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	4185	usd
CY2023Q2	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	4049	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7675177	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7260360	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7507522	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7057954	usd
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	167655	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	202396	usd
CY2024Q2	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	167655	usd
CY2023Q2	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	202396	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	167655	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	202396	usd
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	27700000	usd
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	17000	usd
CY2024	amst	Utilization Utilization	0.80	pure
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	amst	Non Rule10b51 Arrangement Modified Flag NonRule10b51ArrangementModifiedFlag	false
CY2024Q2	amst	Rule10b51 Arrangement Modified Flag Rule10b51ArrangementModifiedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2024	amst	Value Of Common Stock Issued In Exchange For Consulting Services ValueOfCommonStockIssuedInExchangeForConsultingServices		usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	amst	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Granted Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualGrantedTerm2
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense		usd
CY2024	amst	Prior Period Adjustment PriorPeriodAdjustment		usd
CY2023	amst	Prior Period Adjustment PriorPeriodAdjustment		usd
CY2024	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2024Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2023Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2024	amst	Operating Loss Carry Forward Expiration Term OperatingLossCarryForwardExpirationTerm	2027
CY2024	amst	Expire Amount ExpireAmount		usd
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001807166

Files In Submission

Name	View Source	Status
0001213900-24-083458-index-headers.html	Edgar Link	pending
0001213900-24-083458-index.html	Edgar Link	pending
0001213900-24-083458.txt	Edgar Link	pending
0001213900-24-083458-xbrl.zip	Edgar Link	pending
amst-20240630.xsd	Edgar Link	pending
ea0214870-10k_amesite.htm	Edgar Link	pending
ea021487001ex10-4_amesite.htm	Edgar Link	pending
ea021487001ex19-1_amesite.htm	Edgar Link	pending
ea021487001ex23-1_amesite.htm	Edgar Link	pending
ea021487001ex31-1_amesite.htm	Edgar Link	pending
ea021487001ex31-2_amesite.htm	Edgar Link	pending
ea021487001ex32-1_amesite.htm	Edgar Link	pending
ea021487001ex32-2_amesite.htm	Edgar Link	pending
ea021487001ex97-1_amesite.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
amst-20240630_cal.xml	Edgar Link	unprocessable
amst-20240630_def.xml	Edgar Link	unprocessable
amst-20240630_lab.xml	Edgar Link	unprocessable
amst-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0214870-10k_amesite_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMST
Amesite Inc. Stock $amst

2024 Q3 Form 10-K Financial Statement

#000121390024083458 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMST Amesite Inc. Stock $amst

2024 Q3 Form 10-K Financial Statement

#000121390024083458 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMST
Amesite Inc. Stock $amst